GRI Bio, Inc. (GRI) stock
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.27−0.08 (-5.95%)
Close on Nov 18, 2026Market cap $2.78MP/E –Yield –
GRI Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
GRI Bio's revenue for the twelve months ending Mar 31, 2022 was $0. For fiscal 2021 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $100.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $100.00K | – |
See a number that looks wrong?